Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monte Rosa Therapeutics

4.46
-0.0900-1.98%
Post-market: 4.460.00000.00%16:33 EDT
Volume:634.81K
Turnover:2.86M
Market Cap:274.33M
PE:-4.53
High:4.70
Open:4.51
Low:4.38
Close:4.55
Loading ...

Monte Rosa Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
21 Mar

Wedbush Adjusts Price Target on Monte Rosa Therapeutics to $17 From $15, Maintains Outperform Rating

MT Newswires Live
·
21 Mar

Promising Clinical Developments and Strategic Partnerships Drive Buy Rating for Monte Rosa Therapeutics

TIPRANKS
·
21 Mar

Monte Rosa Therapeutics Inc : Wells Fargo Cuts Target Price to $10 From $11

THOMSON REUTERS
·
21 Mar

Wells Fargo Reaffirms Their Hold Rating on Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
21 Mar

U.S. RESEARCH ROUNDUP-Darden Restaurants, Nike, Optinose

Reuters
·
21 Mar

Monte Rosa Therapeutics Inc : JP Morgan Cuts Target Price to $12 From $15

THOMSON REUTERS
·
21 Mar

Monte Rosa Therapeutics Inc : Wedbush Raises Target Price to $17 From $15

THOMSON REUTERS
·
21 Mar

Monte Rosa Therapeutics Files $400 Million Mixed Shelf

MT Newswires Live
·
20 Mar

Monte Rosa Therapeutics Inc - Files for Mixed Shelf Offering of $400 Mln

THOMSON REUTERS
·
20 Mar

Monte Rosa Therapeutics Reports Q4 2024 Financial Results

TIPRANKS
·
20 Mar

BRIEF-Monte Rosa Therapeutics Q4 Operating Expenses USD 47.643 Million

Reuters
·
20 Mar

Monte Rosa Therapeutics Q4 Net Income USD 13.437 Million

THOMSON REUTERS
·
20 Mar

Monte Rosa Therapeutics Inc - Strong Cash Position Expected to Fund Operations Into 2028

THOMSON REUTERS
·
20 Mar

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results From Mrt-6160 and Mrt-2359 Programs

THOMSON REUTERS
·
20 Mar

Press Release: Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

Dow Jones
·
20 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
17 Mar

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

GlobeNewswire
·
11 Mar

3 Top Cancer Biotechs to Keep An Eye On in 2025

Zacks
·
07 Mar

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
24 Feb